Hot Features
Enzolytics, Inc. a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Its patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious dis... Enzolytics, Inc. a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Its patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The company has clinically tested anti-HIV therapeutics. In addition, the company’s proprietary cell line produces human monoclonal antibodies that target and neutralizes the HIV virus. Enzolytics, Inc. is based in Plano, Texas. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.0001 | 12.5 | 0.0008 | 0.0013 | 0.0006 | 39498509 | 0.00099602 | CS |
| 4 | 0.0005 | 125 | 0.0004 | 0.0013 | 0.0004 | 15703885 | 0.00088654 | CS |
| 12 | 0.0006 | 200 | 0.0003 | 0.0013 | 0.0002 | 13130621 | 0.00060955 | CS |
| 26 | 0.0007 | 350 | 0.0002 | 0.0013 | 0.0002 | 10048938 | 0.0005382 | CS |
| 52 | 0.0002 | 28.5714285714 | 0.0007 | 0.0013 | 0.0002 | 8515704 | 0.00046765 | CS |
| 156 | -0.0494 | -98.2107355865 | 0.0503 | 0.06025 | 1.0E-6 | 8691569 | 0.00749647 | CS |
| 260 | -0.2666 | -99.6635514019 | 0.2675 | 0.3195 | 1.0E-6 | 9480905 | 0.05299342 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.